Abstract
The article provides a comparative overview of hepatoprotective drugs and their role in the treatment of liver pathologies. A literature review on the origin and use of hepatoprotectors in liver diseases is presented, and the effectiveness is evaluated.
References
Hepatitis. World Health Organization (WHO). URL: https://www.who.int/health-topics/hepatitis#tab=tab_1
Гладких ФВ, Бєлочкіна ІВ, Кошурба ІВ, Чиж МО. Сучасна гепатопротекція: наративний огляд існуючих підходів та перспективи використання біотехнологічних препаратів. Сучасні медичні технології. 2023;3(58):58-65. https://doi.org/10.34287/MMT.3(58).2023.9
Czigany Z, Tolba RH. New Frontiers in organ preservation and hepatoprotection. Int J Mol Sci. 2022;23(8):4379. doi: 10.3390/ijms23084379
Ткач СМ. Ефективність та безпека гепатопротекторів з точки зору доказової медицини. Здоров'я України. 2009;6:7-10.
Chien CF, Wu YТ, Tsai TH. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed. Chromatogr. 2011.
Fenclova M, Novakova A, Viktorova J, Jonatova P, Dzuman Z, Ruml T, Kren V, Hajslova J, Vitek L, Stranska-Zachariasova M. Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements may account for their reported unsatisfactory and nonreproducible clinical outcomes. Sci Rep. 2019 Jul 31;9(1):11118. doi: 10.1038/s41598-019-47250-0.
Shudi Li, Fei Duan, Suling Li, Baoping Lu. Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis. Received 19 September 2023. Accepted 16 October 2023. DOI: 10.1016/j.aohep.2023.101174
Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database of Systematic Reviews. 2007, Issue 4.
Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med. 1987 Nov 20;83(5A):35-42. doi: 10.1016/0002-9343(87)90849-7. PMID: 3318439.
Skrypnyk RI, Maslova GS. Role of S-ademetionine in prophylaxis of chemotherapy-induced liver injury in patientswith chronic lymphoproliferative disorders. Actual Problems of the Modern Medicine. 2021;21(4):63-67. doi: 10.31718/2077-1096.21.4.63.